Real-world Effectiveness and Safety of Brentuximab Vedotin: A Retrospective Cohort Study from a Tertiary Care Hospital

Background: Brentuximab vedotin (BV) is widely used in CD30-positive lymphomas, but real-world outcomes may differ from clinical trials due to patient heterogeneity and prior treatment exposure. This study evaluated effectiveness, safety, and survival outcomes of BV in routine clinical practice at a tertiary care hospital. Methods: A retrospective cohort study included 37 consecutive patients treated between January 2018 and February 2026. Complete remission (CR) rates were assessed in intention-to-treat (ITT) and evaluable populations. Overall survival and progression-free survival (PFS) was estimated using the Kaplan–Meier analysis. Adverse events were identified from the clinical records. Peripheral neuropathy was additionally assessed through a systematic narrative text search of clinical summaries. Results: The overall CR rate was 24.3% (95% confidence interval [CI], 11.8–41.2) in the ITT population and 33.3% (95% CI, 16.5–54.0) among evaluable patients. CR was numerically higher in Hodgkin lymphoma (HL) than non-HLs (28.6% vs. 21.7%; P = 0.71). Median PFS was 579 days, while median OS was not reached. Peripheral neuropathy was the most frequent adverse event (32.4%). Conclusion: BV shows clinically meaningful real-world effectiveness with a safety profile consistent with previous studies. Peripheral neuropathy remains the principal toxicity. The findings should be interpreted cautiously because of the limited cohort size and potential type II error in subgroup analyses. Larger real-world cohorts are needed to better define the outcomes.